Immunochemosurgery for Advanced Gastric Cancer

  • Jin-Pok Kim
Conference paper


ImmunoChemoSurgery was proved to be effective in preventing cancer recurrence and improving 5 year survival rate of stage III gastric cancer patients. To evaluate the effect of immunochemosurgery, two randomized trials were studied in 1976 and 1981. In first trial, 5-fluorouracil, mitomycin C, and cytosine arabinoside for chemotherapy and OK 432 for immunotherapy were used. The 5 YSR for surgery alone (n=64) and immunochemosurgery (n=73) were 23.4% and 44.6%, respectively, a significant difference. In the second trial, there were three groups: group I, immunochemosurgery (n=159); group II, surgery and chemotherapy (n=77); and group III, surgery alone (n=94). 5-Fluorouracil and mitomycin C for chemotherapy and OK-432 for immunotherapy were administered for 2 years. The 5 YSR of group I was 45.3%, significantly higher than the 29.8% of group II and than the 24.4% of group III. The postoperative DNCB test, T-lymphocyte percentage, PHA and con- A-stimulated lymphoblastogenesis and the ADCC test showed more favorable values in the immunochemosurgery group. Therefore, immunochemosurgery is the best multimodality treatment for advanced gastric cancer.

Key Words

Advanced stomach cancer Radical gastrectomy Immunochemotherapy Cancer recurrence 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kim JP, Park JG (1983) The end-results of surgical treatment of gastric cancer. J Korean Med Assoc 26: 637–642Google Scholar
  2. 2.
    The Gastrointestinal Tumor Study Group (1982) A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer 49: 1362–1366CrossRefGoogle Scholar
  3. 3.
    Taguchi T, Mattori T, Inoue K (1979) Multihospital randomized study on adjuvant chemotherapy with mitomycin ± futraful for gastric cancer. In Jones SE, Salmon SE, eds. Adjuvant Therapy of Cancer II. New York: Grune & Stratton, pp581–586Google Scholar
  4. 4.
    Ota K, Kurita S, Nishimura M (1972) Combination therapy with mitomycin-C, 5- fluorouracil and cytosine arabinoside for advanced cancer in man. Jpn J Cancer Chemother 56: 373–385Google Scholar
  5. 5.
    Mathe G (1971) Active immunotherapy. Adv Cancer Res 14: 1–36PubMedCrossRefGoogle Scholar
  6. 6.
    Morton DL, Eilber FR, Holmes EC (1976) BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma. Med Clin North Am 60: 431–439PubMedGoogle Scholar
  7. 7.
    Rosenberg SA (1985) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Institute 7: 595–616Google Scholar
  8. 8.
    Gutterman JU, Cardenas JO, Blumenschein GR (1976) Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J 2: 1222–1225PubMedCrossRefGoogle Scholar
  9. 9.
    Hattori T, Mori A, Hirata K, Ito I (1972) Five-year survival rate of gastric cancer patients treated by gastrectomy, large dose of mitomycin-C and/or allogeneic bone marrow transplantation. Gann 63: 517–522PubMedGoogle Scholar
  10. l0.
    Okudaira Y, Sugimachi K, Inokuchi K (1982) Postoperative long-term immunochemotherapy for esophageal carcinoma. Jpn J Surgery 12: 249–268CrossRefGoogle Scholar
  11. 11.
    Kim JP, Yoo IH (1978) Relationship between the advance of stomach cancer and the change in immunity. J Korean Surg Soc 20: 195–204Google Scholar
  12. 12.
    Chun SH, Yoo IH, Kim JP (1984) The significance of the measurement of immunosuppressive acid protein (IAP) in various cancer patients. Korean J Immunol 6: 31–42.Google Scholar
  13. 13.
    0rita K, Miwa H, Fukuda H (1976) Preoperative cell-mediated immune status of gastric cancer patient. Cancer 38: 2343–2348PubMedCrossRefGoogle Scholar
  14. 14.
    Kim JP, Choi WJ (1986) A study on histologic type of gastric carcinoma: analysis of clinico pathologic characterization and its implication as a prognostic factor. 18: 194–213Google Scholar
  15. 15.
    Kim JP, Jung SE (1986) Staging patients with gastric cancer and their prognosis. J Korean Cancer Res Assoc 18: 9–13Google Scholar
  16. 16.
    Nissen-Meyer R, Kjellgren K, Malmio K (1978) Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41: 2088–2098PubMedCrossRefGoogle Scholar
  17. 17.
    Suga S, Tsunekawa H, Washino M (1977) Treatment of gastric cancer with special reference to the survivals of the cancer patients treated with multiple combination MFC therapy or immunochemotherapy of MFC plus OK-432 (NSC B116209). Gastroenterol Jpn 12: 20- 46PubMedGoogle Scholar
  18. 18.
    18.Moertel CG, Mittelman JA, Bakemeier RF (1976) Sequential and combination chemotherapy of advanced gastric cancer. Cancer 38: 678–682PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1993

Authors and Affiliations

  • Jin-Pok Kim
    • 1
  1. 1.Department of Surgery, College of MedicineSeoul National University HospitalSeoulKorea

Personalised recommendations